Imugene Ltd gains after therapy indicate tumour reduction in phase 2 study

Imugene

30/06/2023 01:57

** Shares of Australia's clinical-stage oncology co Imugene
Ltd  IMU.AX  rise as much as 7.9% to A$0.096
    ** Co says phase 2 study of HER-Vaxx concluded that
antibodies induced from therapy correlated with tumour reduction
    ** Adds that when compared to chemotherapy alone, the
vaccination resulted in a statistically significant overall
survival benefit
    ** HER-Vaxx is a B-cell immuno-therapy designed to treat
tumours such as gastric, breast, ovarian, lung and pancreatic
cancers
    ** Stock has fallen 38.6% this year as of last close
 

 (Reporting by Jaskiran Singh in Bengaluru)
 ((Jaskiran.Singh@thomsonreuters.com;))